Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Telix Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 17, 2023
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Telix Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : $230.0 million
Deal Type : Licensing Agreement
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Details : The exclusive worldwide licence will allow Telix to repurpose LY3012207 (olaratumab) as a targeting agent for radiopharmaceutical imaging and therapy of cancer.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $5.0 million
October 04, 2022
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : $230.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Olaratumab,Inapplicable
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 21, 2019
Lead Product(s) : Olaratumab,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabectedin,Doxorubicin Hydrochloride,Olaratumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2018
Lead Product(s) : Trabectedin,Doxorubicin Hydrochloride,Olaratumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride,Ifosfamide,Mesna
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 14, 2017
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride,Ifosfamide,Mesna
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaratumab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 24, 2017
Lead Product(s) : Olaratumab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaratumab,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 22, 2017
Lead Product(s) : Olaratumab,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride,Docetaxel,Gemcitabine,Polyferon,Pembrolizumab,Ipilimumab,Interferon Alpha-2b,Bortezomib,Aldesleukin,Trabectedin,Eribulin,Olaratumab,Atezolizumab,Durvalumab,Aveluma,Nivolumab,Larotrectinib,Entrectinib,Avapritinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Fred Hutchinson Cancer Center | University of Washington | Northwell Health | Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 17, 2017
Lead Product(s) : Doxorubicin Hydrochloride,Docetaxel,Gemcitabine,Polyferon,Pembrolizumab,Ipilimumab,Interferon Alpha-2b,Bortezomib,Aldesleukin,Trabectedin,Eribulin,Olaratumab,Atezolizumab,Durvalumab,Aveluma,Nivolumab,Larotrectinib,Entrectinib,Avapritinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Fred Hutchinson Cancer Center | University of Washington | Northwell Health | Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 26, 2016
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 09, 2016
Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable